Smart Immune, a clinical-stage biotechnology company, has recently achieved a major breakthrough by developing an innovative bioproduction method for cultivating T-cell progenitors. Smart Immune is now seeking a Chimeric Antigen Receptor (CAR) construct, that enables precise recognition of tumour antigens, to develop a groundbreaking CAR-T Cell therapy for the treatment of haematological and/or solid tumour malignancies.
Approaches of Interest:
- All mechanisms of action relating to CARs within the oncology field are of interest
- Both conventional CARs (including...